Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 230 clinical trials
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified

refractory multiple myeloma
human chorionic gonadotropin
  • 0 views
  • 16 May, 2022
  • 4 locations
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)

The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple

lenalidomide
bone marrow procedure
  • 0 views
  • 16 May, 2022
  • 3 locations
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants

bone marrow procedure
dexamethasone
bortezomib
proteasome inhibitor
carfilzomib
  • 100 views
  • 25 May, 2022
  • 6 locations
A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI

refractory multiple myeloma
  • 0 views
  • 25 May, 2022
  • 7 locations
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma

with relapsed and refractory multiple myeloma (RRMM).The study will consist of two parts: dose escalation (Part 1) and dose expansion (Part 2).The dose escalation (Part 1) of the study will evaluate

  • 0 views
  • 26 May, 2022
  • 2 locations
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.

monoclonal protein
monoclonal antibodies
daratumumab
refractory multiple myeloma
measurable disease
  • 59 views
  • 26 May, 2022
  • 17 locations
BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed/refractory multiple myeloma

bortezomib
immunomodulatory imide drug
daratumumab
carfilzomib
lenalidomide
  • 0 views
  • 27 May, 2022
  • 3 locations
MagnetisMM-8: Study Of Elranatamab (PF-06863135) Monotherapy in Chinese Participants With Refractory Multiple Myeloma

stage design to evaluate the efficacy and safety in Chinese participants. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma

refractory multiple myeloma
  • 0 views
  • 27 May, 2022
  • 8 locations
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma

  • 0 views
  • 28 May, 2022
  • 3 locations
Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

the study treatment that combines the following drugs: daratumumab, carfilzomib, lenalidomide, dexamethasone in subjects who have a recent diagnosis of multiple myeloma (MM). Normal plasma (blood

bone marrow procedure
ejection fraction
cancer
daratumumab
dexamethasone
  • 0 views
  • 28 May, 2022
  • 1 location